View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
In view of the important priority of developing new agents for the treatment of infectious disease and related malignancies, interested parties should notify this office in writing no later than January 21, 1997. Respondents will then be provided an additional 30 days for the filing of formal proposals.
In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than [FR: insert date 60 days after date of publication]. Respondents will then be provided an additional 30 days for the filing of formal proposals.
In view of the high interest in developing Anti-Cancer Vaccines in general, interested parties should notify the NCI Office of Technology Development in writing no later than December 4, 1996.
In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than October 18, 1996. Respondents will then be provided an additional 30 days for the filing of formal proposals.
In view of the high interest for developing GFP for applications and diagnostics, interested parties should notify the NCI Office of Technology Development in writing no later than thirty (30) days from the date of this announcement. Respondents will then be provided an additional thirty (30) days for submitting formal CRADA proposals.
In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than July 12, 1996. Respondents will then be provided an additional 30 days for the filing of formal proposals.
